Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment

The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer

(2020) Lei Ding et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC).

(2020) Pin Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results.

(2020) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical characterization of SHR 6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models

(2019) Fei Long et al.   CANCER SCIENCE

Molecular Classification of Breast Cancer

(2019) Julia Y.S. Tsang et al.   ADVANCES IN ANATOMIC PATHOLOGY

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

(2019) Sobhani et al.   Cells

Resveratrol chemosensitizes adriamycin‐resistant breast cancer cells by modulating miR‐122‐5p

(2019) Wei Zhang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM

(2019) Xia Cheng et al.   Breast Cancer

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

(2019) Antoinette R Tan et al.   LANCET ONCOLOGY

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

(2019) J M Weiss et al.   ANNALS OF ONCOLOGY

Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells

(2019) Chang Hee Jeong et al.   Antioxidants

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

(2019) Keelan Z. Guiley et al.   SCIENCE

Panduratin A Inhibits Cell Proliferation by Inducing G0/G1 Phase Cell Cycle Arrest and Induces Apoptosis in Breast Cancer Cells

(2018) Qiuming Liu et al.   Biomolecules & Therapeutics

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

(2018) HS Rugo et al.   CANCER RESEARCH

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

(2018) J.L. Ethier et al.   EUROPEAN JOURNAL OF CANCER

C-glycosyl flavone from Urginea indica inhibits proliferation & angiogenesis & induces apoptosis via cyclin-dependent kinase 6 in human breast, hepatic & colon cancer cell lines

(2018) RamaRao Malla et al.   INDIAN JOURNAL OF MEDICAL RESEARCH

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

Galangin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Mitochondrial Pathway and Phosphatidylinositol 3-Kinase/Akt Inhibition

(2018) Dan Liu et al.   PHARMACOLOGY

Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology

(2018) Shuji Ogino et al.   Annual Review of Pathology-Mechanisms of Disease

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs

(2018) Robert Roskoski   PHARMACOLOGICAL RESEARCH

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field

(2017) Clinton Yam et al.   ONCOLOGIST

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

(2017) Shenghui He et al.   Science Translational Medicine

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity

(2016) Frank E. Kwarcinski et al.   ACS Chemical Biology

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Insights into APC/C: from cellular function to diseases and therapeutics

(2016) Zhuan Zhou et al.   Cell Division

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

(2016) Andrea Rocca et al.   Therapeutic Advances in Medical Oncology

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Spatiotemporal regulation of the anaphase-promoting complex in mitosis

(2015) Sushama Sivakumar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A historical overview of protein kinases and their targeted small molecule inhibitors

(2015) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors

(2015) Marion Peyressatre et al.   Cancers

Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages

(2014) Lihuan Cao et al.   BMC EVOLUTIONARY BIOLOGY

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression

(2014) Paul Lochhead et al.   MODERN PATHOLOGY

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

(2014) Anil M Narasimha et al.   eLife

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

The ubiquitin proteasome system — Implications for cell cycle control and the targeted treatment of cancer

(2013) Florian Bassermann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

(2013) A. M. Karst et al.   CANCER RESEARCH

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

(2013) Monica M. Mita et al.   Clinical Breast Cancer

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

(2013) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space

(2013) Oscar P. J. van Linden et al.   JOURNAL OF MEDICINAL CHEMISTRY

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Emerging drug profile: cyclin-dependent kinase inhibitors

(2013) James S. Blachly et al.   LEUKEMIA & LYMPHOMA

Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma

(2013) Elisabetta Kuhn et al.   MODERN PATHOLOGY

Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host and disease

(2013) Shuji Ogino et al.   MODERN PATHOLOGY

The Molecular Balancing Act of p16 INK4a in Cancer and Aging

(2013) Kyle M. LaPak et al.   MOLECULAR CANCER RESEARCH

Control of cell cycle transcription during G1 and S phases

(2013) Cosetta Bertoli et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors

(2012) Vandana Lamba et al.   CURRENT PHARMACEUTICAL DESIGN

How many molecular subtypes? Implications of the unique tumor principle in personalized medicine

(2012) Shuji Ogino et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Melanoma: from mutations to medicine

(2012) H. Tsao et al.   GENES & DEVELOPMENT

Price To Be Paid for Two-Metal Catalysis: Magnesium Ions That Accelerate Chemistry Unavoidably Limit Product Release from a Protein Kinase

(2012) Douglas M. Jacobsen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Approaches to discover non-ATP site kinase inhibitors

(2012) Lori Krim Gavrin et al.   MedChemComm

The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling

(2011) Arvin C. Dar et al.   Annual Review of Biochemistry

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma

(2011) Christopher Abdullah et al.   CELL CYCLE

Cancer immunology—analysis of host and tumor factors for personalized medicine

(2011) Shuji Ogino et al.   Nature Reviews Clinical Oncology

Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors

(2011) Natalia G. Starostina et al.   TRENDS IN CELL BIOLOGY

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

(2010) Christophe Le Tourneau et al.   EUROPEAN JOURNAL OF CANCER

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Protein kinases: evolution of dynamic regulatory proteins

(2010) Susan S. Taylor et al.   TRENDS IN BIOCHEMICAL SCIENCES

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

(2009) D. S. Boss et al.   ANNALS OF ONCOLOGY

Recent developments in cyclin-dependent kinase biochemical and structural studies

(2009) Aude Echalier et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy

(2009) M. Y. Zhao et al.   CLINICAL CANCER RESEARCH

Stemming Resistance to HER-2 Targeted Therapy

(2009) Philippe L. Bedard et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

(2009) Fabio Zuccotto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation

(2009) L. Bockstaele et al.   MOLECULAR AND CELLULAR BIOLOGY

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

(2009) K. F. Byth et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin-dependent kinases: a family portrait

(2009) Marcos Malumbres et al.   NATURE CELL BIOLOGY

The structure of CDK4/cyclin D3 has implications for models of CDK activation

(2009) T. Takaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of human CDK4 in complex with a D-type cyclin

(2009) P. J. Day et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p27Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes

(2008) A. Ray et al.   MOLECULAR AND CELLULAR BIOLOGY